[Thromboembolism prevention with low-molecular-weight heparins. Risks, events and costs].
Hansen
N
N
Institut für Empirische Gesundheitsökonomie, Burscheid.
Bruchhausen
Y
Y
Rychlik
R
R
D003362:Cost-Benefit Analysis; D005858:Germany; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy / Q000191:economics*
D006495:Heparin, Low-Molecular-Weight